Atalay, S. (2020) “Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study”, Acta Dermato-Venereologica, 100(19), pp. 1–7. doi: 10.2340/00015555-3692.